Signaling through the T cell receptor (TCR) controls adaptive immune responses. Antigen binding to the TCR subunits transmits signals through the plasma membrane to induce phosphorylation of the CD3 cytoplasmic tails by incompletely understood mechanisms. Here we show that cholesterol bound to the TCR transmembrane region keeps the resting TCR in an inactive conformation that cannot be phosphorylated by active kinases. Only TCRs that spontaneously detach from cholesterol can switch to the active conformation and be phosphorylated. Indeed, by modulating cholesterol binding genetically or enzymatically, we can switch the TCR between the inactive and active states. The active conformation is stabilized by binding to peptide-MHC ligands, which thus control TCR signaling.
INTRODUCTION
Membrane lipids are thought to play a passive role in the function of transmembrane (TM) proteins by embedding and organizing them into lipid microdomains (Coskun and Simons, 2011) . However, in a few cases it was shown that the TM regions of proteins and certain lipids interact in a specific manner (Cherezov et al., 2007; Contreras et al., 2012; Coskun and Simons, 2011; Hanson et al., 2008) . The functional implications of these interactions remain mostly unknown. We have previously found that the TCR specifically binds to cholesterol in resting cells to aid formation of TCR nanoclusters (Molnar et al., 2012) . Here, we investigate whether this binding also regulates TCR signaling.
The TCR consists of eight TM proteins organized in dimers; TCR, CD3, CD3, CD3.
TCR binds to peptides presented on major histocompatibility complex (pMHC) molecules (Davis et al., 1998) . The information on pMHC binding is transferred to the CD3 subunits, which are subsequently phosphorylated on immunoreceptor tyrosine-based activation motifs (ITAMs) by the Src-family tyrosine kinase Lck (Iwashima et al., 1994) . Phospho-CD3s serve as docking sites for the kinase ZAP70 that becomes active at the TCR and transmits downstream signals.
The mechanism of signal transduction from the extracellular domains of TCR through the membrane, resulting in phosphorylation of the CD3 cytoplasmic tails, is poorly understood (Davis and van der Merwe, 2006) . Any mechanistic model needs to take into account that in resting T cells a large proportion of Lck is active (Nika et al., 2010 ), yet CD3s are not phosphorylated. Accordingly, several models have been proposed, including spatial segregation of phosphatases or sequestration of the CD3 chains (James and Vale, 2012; Kuhns and Davis, 2012; Shi et al., 2013; van der Merwe and Dushek, 2011; Xu et al., 2008) .
Using protease resistance, FRET and various biochemical approaches, it was shown that the quaternary structure of the TCR changes upon ligand binding, resulting in a reversible conformational change in the cytoplasmic tails of the CD3 subunits (Gil et al., 2002; Lee et 4 al., 2015; Risueno et al., 2005; Risueno et al., 2008) . These studies led to the permissive geometry model of TCR activation (Minguet and Schamel, 2008; Minguet et al., 2007) . One hallmark of this structural change is the regulation of the accessibility of a proline-rich sequence (PRS) in the CD3 cytosolic tail. In the resting, non-ligand-bound TCR state, the PRS cannot bind to the SH3.1 domain of the adaptor protein Nck hereafter referred to as inactive TCR or TCRI. By contrast, in the ligand-bound TCR state, the PRS can bind to SH3.1; the TCR in this state is called here the active TCR or TCRA. The switch from TCRI to TCRA is required for T-cell activation. This has been demonstrated by synthetic ligands that only evoked CD3 phosphorylation when the TCRA form was stabilized and by identifying point mutations in the extracellular stalk region of CD3 (such as K76T and C80G) that prevented the TCRI to switch to TCRA and abrogated CD3 phosphorylation (Blanco et al., 2014; Martinez-Martin et al., 2009 ).
Here, we provide mechanistic and quantitative insight into how pMHC-binding results in the phosphorylation of the TCR. We present biochemical, genetic and functional evidence that cholesterol and pMHC/antibody ligands regulate the allosteric transitions of the TCR: in the resting state cholesterol binding stabilizes TCRI, ligand binding stabilizes TCRA, and only TCRA can be phosphorylated.
RESULTS

Cholesterol binds to TCR only in the resting, inactive TCR
Within the TCR, cholesterol specifically binds to TCR (Molnar et al., 2012) . We asked whether this binding changes upon switching the conformation from TCRI to TCRA in living cells. We grew Jurkat T cells in the presence of a radioactive cholesterol analogue with a UVinducible cross-linker group (photocholesterol) (Thiele et al., 2000) . The cells were left unstimulated or stimulated with anti-CD3 antibodies for different times before exposure to 5 UV light ( Figure 1A ). Subsequently, surface TCRs were isolated to detect the radioactive cholesterol signals by SDS-PAGE and autoradiography ( Figure 1B ). Anti-CD3 Western blotting (WB) served as loading control. Binding of cholesterol to TCR was reduced by more than 50% upon antibody-binding to the TCR. Alternative experimental settings corroborated this finding ( Figure S1A and S1B). In parallel, an SH3-pull-down (PD) assay using the SH3.1 domain of Nck (Gil et al., 2002) was done to quantify the amount of TCRA ( Figure 1C and S1C). The reduction of cholesterol binding occurred concomitantly with the switch to TCRA and might have preceded phosphorylation of CD3 ( Figure 1C ). As a control, UV-irradiation alone had no effect on the TCRI-TCRA equilibrium ( Figure S1D ). Thus, in living cells cholesterol preferentially binds to TCRI.
To determine whether the inability of TCRA to bind cholesterol is an intrinsic property of the TCR, we used a recently developed cholesterol-PD assay (Beck-Garcia et al., 2013) ( Figure   1D ). Cholesterol binding was indeed reduced when TCRA accumulated due to anti-CD3 or anti-TCR binding and was independent of phosphorylation, since it also occurred at 0°C and in the presence of the Src kinase inhibitor PP2 ( Figure 1E ). Bub3, which also binds to the lipid beads (Beck-Garcia et al., 2013) , served as a loading control. This reduction was also seen in primary human T cells ( Figure S1E ). In contrast to cholesterol beads, TCR binding to stearate or palmitate beads was independent of the TCR conformational state ( Figure S1F , S1G, 1F and S1H). Thus, the conformational state of the TCR specifically correlated with cholesterol binding ( Figure 1F ).
To support the finding that cholesterol preferentially binds to TCRI compared to TCRA, we used a CD3 with a mutation (K76T) in its extracellular stalk region, which favors the inactive conformation (Martinez-Martin et al., 2009) (Figure 1G ). We expressed murine wild type (wt) and K76T CD3 in Jurkat cells (Figure S1I) . Consistent with its inability to switch to TCRA, similar amounts of K76T TCR bound to cholesterol beads with or without antibody 6 stimulation ( Figure 1H ). Altogether, these data confirm that cholesterol binding to the TCR is conformation-selective.
Cholesterol binding keeps the TCR in the non-phosphorylatable state
To construct a TCR chain that cannot bind cholesterol, we took advantage of our finding that the  TCR does not bind cholesterol ( Figure S2A ). We surmised that cholesterol binds to the TCR TM region. Thus, a single-chain Fv fragment-tagged TCR chain (scTCR) (Gil et al., 2002 ) mutant was constructed, in which the TM region was replaced with the TM from the human TCR2 chain (TMchim, Figures 2A, S2B and S2C) . The TMchim TCR was expressed on the surface of TCR-negative Jurkat cells to the same levels as the wt TCR ( Figure S2D ).
Native gel and epitope accessibility analyses suggested that the TMchim TCR assembled in the same stoichiometry and a similar structure as the wt TCR ( Figures S2E and S2F ).
However, the resting TMchim TCR bound more weakly to cholesterol compared to the resting wt TCRs ( Figure 2B ), indicating that indeed the TCR TM region binds cholesterol.
The residual binding of the TMchim TCR to the cholesterol-beads was not further decreased by antibody-stimulation and had the same level as the cholesterol-binding of the antibodystimulated wt TCR ( Figure 2B ). This suggested that the TMchim TCR does not bind to cholesterol. As a control, TMchim and wt TCRs bound equally well to palmitate-coupled beads ( Figure S2G ). Importantly, reduced cholesterol binding to the TMchim TCR promoted the active conformation as seen by increased binding in the SH3-PD assay in both resting and anti-CD3-stimulated conditions ( Figure 2C ). The increased levels of TCRA resulted in enhanced basal and antibody-induced phosphorylation of CD3 ( Figure 2D ). This increase in CD3 phosphorylation was physiologically relevant, since we also detected enhanced Erk phosphorylation and upregulation of the activation marker CD69 in the resting and in the 7 antibody-stimulated situation ( Figure 2E and S2H). In conclusion, genetically ablating the cholesterol-binding region in the TCR increased the frequency of TCRA indicating that cholesterol binding regulates the TCRI-TCRA equilibrium.
Cholesterol removal causes TCRs to switch to the active state
Next, we tested whether cholesterol stabilizes the inactive state in native, wt TCRs ( Figure   3A ). Reduction of cell membrane cholesterol levels by treatment with cholesterol oxidase, which converts cholesterol to cholest-4-en-3-one (Gimpl and Gehrig-Burger, 2007) , led to a 2-fold increase in the proportion of TCRA ( Figure 3B ). Moreover, lowering cholesterol levels enhanced basal CD3 and Erk phosphorylation ( Figure 3B and 3C) as well as CD69 upregulation ( Figure S3A ) in Jurkat cells. Enhanced Erk phosphorylation upon cholesterol reduction was also seen in primary human T cells ( Figure S3B ). Cholesterol oxidase treatment neither led to decreased cell viability ( Figure S3C ) nor rendered the cells unresponsive to anti-CD3 stimuli (data not shown). Switching to TCRA and increased CD3 phosphorylation were also seen after we extracted cholesterol using methyl--cyclodextrin (mCD, Figure S3D ).
The induction of signaling by cholesterol removal using mCD is in line with the literature (Kabouridis et al., 2000; Rouquette-Jazdanian et al., 2006) , and could be due to either the accumulation of TCRA or to other effects of cholesterol reduction, such as altered membrane microdomain organization (Horejsi, 2003) . To test whether the stimulating effect of cholesterol is TCR-dependent, we used TCR-negative Jurkat cells. Cholesterol oxidase treatment did not lead to increased Erk phosphorylation in cells lacking a TCR ( Figure 3D ).
Hence, enhanced signaling upon cholesterol extraction was TCR-dependent, and thus most likely caused by the accumulation of TCRA. Consistent with this conclusion, we found that in cells expressing the TMchim TCR, which does not bind cholesterol, cholesterol oxidation did not further increase the amount of TCRA or Erk phosphorylation ( Figure S3E ). Together, 8 these data suggest that cholesterol-binding to the TCR keeps the TCR in the TCRI state to prevent spontaneous signaling.
Cholesterol detachment and switching to TCRA favor CD3 phosphorylation
To confirm a gatekeeper function of cholesterol, we investigated whether cholesterol removal from the TCR is required for CD3 phosphorylation. We grew Jurkat cells in radioactive photocholesterol as before. Using UV light, we covalently linked cholesterol to the TCRs, hypothesizing that cholesterol-linked TCRs would not be able to spontaneously switch to the TCRA form, and therefore would not become phosphorylated. To detect CD3 phosphorylation, we used the phosphatase inhibitor pervanadate that prevents removal of phosphate groups from CD3, hence allowing phosphorylated TCRs to accumulate; of note, pervanadate does not itself affect the TCR's conformational state (Gil et al., 2002; O'Shea et al., 1992) . First, we cross-linked radioactive cholesterol to the TCRs and then treated the cells with pervanadate ( Figure 4A and 4B, lane 1). After lysis, phosphorylated proteins were purified. The autoradiography shows that cholesterol-linked TCRs were not phosphorylated (lane 1). Due to the low amount of radioactive cholesterol, most TCRs were bound to endogenous unmodified cholesterol ( Figure 4A , lower panel), and those TCRs were phosphorylated as demonstrated by WB ( Figure 4B , lane 1). This indicated that the cholesterol-linked TCRs were locked in a non-phosphorylatable state, and that cholesterol needs to dissociate from the TCR before the TCR can be phosphorylated.
In contrast, when the cells were first treated with pervanadate to phosphorylate the TCRs and then exposed to UV light ( Figure 4A and 4B, lane 2), radioactive and phosphorylated TCRs were detected. This served as a control for cross-linking of radioactive cholesterol to TCR and indicated that phosphorylated TCRs can switch to the TCRI state and then bind to cholesterol again. Indeed, phosphorylated TCRs could switch back to TCRI ( Figure 4C , SH3-PD), and bind to cholesterol-coupled beads ( Figure 4C , cholesterol-PD). UV light 9 illumination alone did not alter the phosphorylation of the TCR ( Figure S4A ). In conclusion, cholesterol-bound TCRs cannot be phosphorylated in living cells, confirming that only those TCRs that are not bound to cholesterol are capable of switching to TCRA in order to be phosphorylated.
TCRs can spontaneously switch to TCRA (de la Cruz et al., 2011; Mingueneau et al., 2008) and Figure 4B suggests that only TCRA can be phosphorylated ( Figure 4D , upper panel). To test if the switch to TCRA is required for phosphorylation, we used the K76T CD3 mutant, whose capacity to switch to the TCRA conformation is reduced (Martinez-Martin et al., 2009) ( Figure 4D , lower panel). The murine wt and K76T CD3-expressing Jurkat cells were treated with pervanadate, lysed, and the TCR was immuno-precipitated ( Figure 4E ). We used twice the amount of K76T CD3-expressing cells for the IP to compensate for the two-fold lower TCR expression level ( Figure S1I ). Indeed, similar amounts of TCRs were separated by SDS-PAGE ( Figure 4E , lowest panel), but a smaller fraction of CD3 and CD3 were phosphorylated in the K76T mutant (only TCRI) compared to the wt TCR (spontaneously switching to TCRA). Likewise, ZAP70 was more readily recruited to, and phosphorylated at, the wt TCR ( Figure 4E and S4B ). In addition, the upregulation of CD69 was impaired when the K76T CD3-containing TCR was stimulated with anti-CD3 compared to the wt TCR ( Figure S4C ).
Further, to compare cells with equal surface TCR expression levels, we used flow cytometry.
We stimulated wt and K76T CD3-expressing Jurkat cells with pervanadate and stained them for flow cytometry against mouse CD3, phospho-ZAP70 and phospho-Erk. Cells expressing equal levels of mouse CD3 were gated. Again the downstream signaling events, such as phosphorylation of ZAP70 and Erk, were reduced when the K76T CD3-containing TCR was stimulated ( Figure S4D , S4E and S4F).
We thus conclude that CD3 phosphorylation by a ligand-independent stimulus requires that the TCR spontaneously adopt the active conformation.
Lck can only phosphorylate TCRA
To characterize the mechanism that allows TCRA, but not TCRI, to be phosphorylated, we used a synthetic system in which the wt scTCR (Gil et al., 2002) was purified using nitrophenol-coupled beads without altering the TCR's conformational state. We then left the sample untreated ( Figure 5A , TCRI) or added anti-CD3 and anti-TCR antibodies that mimic ligand binding and stabilize TCRA . The system was supplemented with recombinant active Lck performing the in vitro kinase assay with the TCRs immobilized on the beads. In the untreated sample hardly any CD3 phosphorylation was detected ( Figure   5B ), suggesting that the CD3 tails were protected in the TCRI conformation. Strikingly, CD3, CD3 and CD3 ( Figure 5B , 5C and S5A) were more strongly phosphorylated when TCRA was stabilized by antibody binding. Further, the amount of TCRA ( Figure 5B , lower panel) correlated with the amount of TCRs that were phosphorylated (Figure 5B, upper panel) and with the intensity of downstream signaling ( Figure S5B ). Likewise, recombinant Lck could only phosphorylate membrane-embedded TCRs when anti-CD3 antibodies ( Figure   5D ) or pMHC tetramers stabilized TCRA ( Figure S5C ). Importantly, Lck autophosphorylation and LAT phosphorylation by Lck were detected independently of the TCR's conformational state, demonstrating that (i) Lck was active under all conditions and (ii) the TCR state specifically regulated the accessibility of the TCR cytoplasmic tails for phosphorylation (Figure 5B and 5D) . Since the recombinant Lck did not contain any fatty acid modifications, differential TCRA versus TCRI phosphorylation cannot be caused by differential interaction of Lck with the detergent micelle. Addition of cholesterol to our synthetic reconstitution system reduced both the spontaneous and antibody-stabilized accessibility of the CD3's PRS
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(TCRA) and the amount of CD3 phosphorylation ( Figure 5E , F). In conclusion, an active kinase can phosphorylate CD3 only when the TCR is in the active state.
An allostery model for the regulation of TCR activity
Based on our understanding of the initial steps of TCR triggering, we propose a quantitative model that describes how cholesterol and pMHC control the conformational equilibrium between the TCRI and TCRA states ( Figure 6A) . This model provides a mechanistic basis for our experimental observations and is based on five premises: (1) The TCR is in conformational equilibrium with the equilibrium constant L = [TCRI]/ [TCRA] . Thus, the TCR can switch spontaneously in the absence of ligand to the active state, as suggested experimentally (de la Cruz et al., 2011; Mingueneau et al., 2008) (Figures 2 and 3) . (2) The conformational switch is reversible in that TCRA can revert to TCRI. This was shown earlier . (3) Cholesterol binds to TCRI, but not to TCRA, with the affinity constant Kc, hence stabilizing TCRI (Figure 1 ). This is consistent with our finding that the conformational equilibrium of a mutant TCR that cannot bind cholesterol is shifted towards TCRA ( Figure 2 ). (4) Only TCRA can be phosphorylated, suggested by our results using the in vitro kinase assay ( Figure 5 ) and our findings that switching to TCRA through reduced cholesterol binding results in spontaneous signaling (Figure 2 and 3) . (5) Binding of at least dimeric soluble pMHC stabilizes TCRA, while monovalent soluble pMHC can bind to both TCRA and TCRI as suggested earlier . According to previous findings, we consider a preformed nanocluster of two TCRs (Schamel et al., 2005) Stimulation of wt T cells with anti-CD3 experimentally increased the fraction of TCRA from 2% to 16% ( Figure S6A ). Fitting the model to these numbers predicted a TCRA fraction of 43% for the non-cholesterol binding TMchim TCR after the same anti-CD3 stimulus. We experimentally confirmed this prediction (40 ± 4%, Figure 6B ). Taken together, these data
show that this allosteric model quantitatively describes the active-inactive conformational equilibrium of the TCR and its regulation by cholesterol (all model parameters are listed in Figure S6B ).
An unexpected prediction of the model was that the TCR conformation controls the TCR's avidity for pMHC, because only TCRA can bind pMHC bivalently ( Figure 6A ). To test this prediction, we used the OT-1 TCR, which binds to OVA-H2- Figure 6C ; points) (Blanco et al., 2014) . Fitting the model to these data ( Figure 6C , lines), we estimate Ka = 0.1 M -1 and Kb = 1755, thus indicating that pMHC binding by TCRA is preferred. Similar results were obtained when the MHC-CD8 interaction was not prevented ( Figure S6C ). In summary, the model predicts, and the experimental data confirm, strong reduction of pMHC tetramer binding by a mutant TCR that cannot switch to TCRA.
Collectively, these data define the parameters for the allostery model of TCR regulation. The predicted dose-responses to pMHC ligand concentrations show quantitative control by cholesterol of TCRA levels ( Figure 6D ). Moreover, cholesterol, through controlling the activeinactive state equilibrium, influences pMHC binding ( Figure 6E ). In conclusion, cholesterol emerges as a negative allosteric regulator of TCR activity that guards both the resting state of the TCR and modulates TCR activation by ligand.
DISCUSSION
In recent years, specific interactions between TM regions of proteins and membrane lipids have been discovered (Cherezov et al., 2007; Contreras et al., 2012; Coskun et al., 2011; Hanson et al., 2008) but not much is known about their functions. Here, we demonstrate that cholesterol binding to the TM region of TCR controls T-cell activation by regulating an allosteric switch in the TCR that exposes the CD3 PRS (active TCR or TCRA) and permits the phosphorylation of the ITAM tyrosines. This is achieved by selective cholesterol binding to the inactive TCR conformation (TCRI), which prevents spurious TCR activation and sets the activation threshold for pMHC ligands. Our findings thus show how a specific membrane lipid regulates receptor function.
Our data indicate that prior to stimulation, the TCR exists in equilibrium between the TCRI and TCRA state. This is in line with earlier reports showing that a fraction of the TCRs are spontaneously in the TCRA state in unstimulated cells (de la Cruz et al., 2011; Mingueneau et al., 2008) . We found that on a resting, mature T cell, 98% of the TCRs are in the TCRI state, To prove that the capacity to be phosphorylated is dependent on the conformational state of the TCR, we used the phosphatase inhibitor pervanadate, which leads to accumulation of phosphate groups at CD3 (O'Shea et al., 1992) without manipulating the TCRI-TCRA equilibrium (Gil et al., 2002) . Neither the K76T CD3-containing TCR, which cannot switch to TCRA, nor covalently cholesterol-linked TCRs, which are locked in the TCRI state, were efficiently phosphorylated upon pervanadate treatment. This indicated that CD3
phosphorylation by a ligand-independent stimulus requires that the TCR spontaneously adopts the TCRA conformation to be phosphorylated.
Our results raise the question of how ligand binding removes cholesterol from TCRI. Our quantitative allosteric model suggests that cholesterol spontaneously associates to and dissociates from the TCRI, with 50% of the TCRIs being cholesterol-bound. Only when a
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TCRI is not bound to cholesterol, it can spontaneously switch to TCRA. Then the TCRA state can be stabilized by pMHC binding and cholesterol rebinding to TCRA is prevented. We have previously hypothesized that ligand binding induces the TCR to switch to the active state (Gil et al., 2002; Minguet et al., 2007; Risueno et al., 2005) . However, our new data suggest that this switch occurs spontaneously and ligand binding stabilizes TCRA. Monovalent pMHC binding might be enough to stabilize the TCRA conformation, when pMHC is tethered to a surface. However, we have used soluble pMHC tetramers to quantify pMHC binding. For soluble ligands it was shown that minimally, a dimeric pMHC is required to stabilize TCRA (Minguet and Schamel, 2008) and thus, foster downstream signaling (Boniface et al., 1998; Cochran et al., 2000; Krogsgaard et al., 2005) . This might be true in the case that the TCR was a preformed nanocluster (Schamel et al., 2005) or that two TCR monomers were held together by bivalent pMHC binding. The change in the quaternary structure of the TCR might include reorientation of one CD3 in respect to the second CD3 (Lee et al., 2015) without structural changes within one TCR heterodimer (Minguet and Schamel, 2008) .
Using quantitative data on the TCR conformational switch and our understanding of the role of cholesterol in regulating the TCRI-TCRA equilibrium, we developed a data-based mathematical model of the allosteric regulation of TCR phosphorylatability. In absence of cholesterol, 7% of the TCRs are in the TCRA state. However, cholesterol tightens this regulation and only 2% of the TCRs are in the TCRA state. This 3.5-fold increase corresponds to the narrow range of 2-4-fold increases in ITAM phosphorylation or ZAP70 recruitment upon TCR activation (Deswal et al., 2011; Kim and White, 2006; Steinberg et al., 2004) . This increase is physiologically significant, since it results in initiation of TCR signaling as seen by phosphoErk and CD69 upregulation. As allosteric effects are reciprocal (Monod et al., 1965) Using CD3 mutants and modified ligands, it was shown that the TCRA state, as measured by the exposure of the CD3 PRS, was required for ligand-induced CD3 phosphorylation and T cell activation (Martinez-Martin et al., 2009; Minguet et al., 2007) . Since only the exposed PRS binds to Nck, it was suggested that Nck plays a role in CD3 phosphorylation (Blanco et al., 2014; Borroto et al., 2013; Mingueneau et al., 2008) . However, our data suggest an alternative mechanism. Only in the TCRA state, and not in the TCRI state, the ITAM tyrosines are phosphorylatable. This provides a molecular mechanism for how non-triggered TCRs are protected from phosphorylation in the presence of active Lck (Nika et al., 2010) . Hence, our model explains how cholesterol aids to keep the TCR inactive and how ligand-binding induces TCR phosphorylation by stabilizing TCRA. The molecular events described in our novel model most likely precede the phosphorylation-or Ca 2+ influx-induced dissociation of the CD3 and CD3 cytoplasmic tails from the plasma membrane (Aivazian and Stern, 2000; Shi et al., 2013; Xu et al., 2008) .. In fact these mechanisms might serve to facilitate further phosphorylation and hence, sustain T-cell activation signals.
It has been reported that extraction of cholesterol using methyl--cyclodextrin (mCD)
followed by antibody stimulation leads to reduced TCR signaling, most likely due to disruption of lipid rafts (Montixi et al., 1998; Xavier et al., 1998) . In contrast, when mCD is used as a stimulus, i.e. when signaling is analyzed immediately after the mCD treatment, the TCR is triggered (Kabouridis et al., 2000; Rouquette-Jazdanian et al., 2006) . We now provide a molecular mechanism for the stimulatory effect of mCD, by demonstrating that lowering 17 cholesterol levels leads to an increase in TCRA that can be phosphorylated. Our data also suggest that cholesterol exerts its effect on TCR signaling directly at the TCR, since (i) cholesterol oxidation did not induce signaling in a TCR-deficient T cell line, (ii) the TMchim TCR showed enhanced signaling and (iii) binding of cholesterol to the TCR prevented CD3 phosphorylation.
Our new findings can be integrated with existing models of TCR activation and several molecular events might occur simultaneously. The change in the conformational state of the TCR most likely includes the TM regions, such as the one of TCR (this study) and CD3 (Lee et al., 2015) , the cytoplasmic tails of CD3, CD3, CD3 and CD3 (Gil et al., 2002; Risueno et al., 2008; Xu et al., 2008) Cholesterol is also involved in the formation of TCR nanoclusters (Molnar et al., 2012; Schamel et al., 2005) , and thus has two apparently opposing effects in respect to pMHC binding. By inducing TCR nanoclustering, cholesterol enhances the avidity towards pMHC tetramers. In contrast, by stabilizing the TCRI state, cholesterol decreases the avidity. Using our mathematical model, we simulated reduction of the cholesterol concentration and found that the impact of changing the TCRI-TCRA equilibrium on pMHC tetramer binding is rather small (maximal 3 fold). Furthermore, experimental cholesterol-extraction reduced pMHC tetramer-binding to T cells (Fahmy et al., 2001; Molnar et al., 2012) . Thus, the nanoclustering function of cholesterol predominates in regulating the avidity towards pMHC tetramers. We suggest that cholesterol has a dual role at the TCR, enhancing the sensitivity to agonistic ligands but still restraining spontaneous signaling, which might be especially important in the case of antigen-experienced T cells (Kumar et al., 2011) . Since different T cell developmental and differentiation stages contain different levels of cholesterol (Brumeanu et al., 2007; Kaech et al., 2002; Tani-ichi et al., 2005) , it could be that changes in the plasma membrane cholesterol level contribute to regulate TCR activity and thereby, T cell sensitivity in vivo.
In conclusion, we show here that the specific interaction of the TCR TM region with cholesterol regulates TCR triggering and T cell activation. In contrast to the long-standing assumption that the plasma membrane is an inert solvent that does not impact on the conformation or activity of membrane proteins, we clearly demonstrate that cholesterol binding to the TCR regulates CD3 phosphorylability. Lipids therefore not only play a role in the activation of T cells but also in guarding their resting state. Our work provides a novel paradigm for how the activity of TM proteins can be regulated.
EXPERIMENTAL PROCEDURES Photocholesterol labelling
[3-3 H]6-azi-5-cholestan-3-ol (radioactive UV-light cross-linkable cholesterol, photocholesterol) was provided by Dr. Thiele. Jurkat cells were incubated for 16 hours in lipid-free medium containing a radioactive cross-linkable cholesterol-mCD complex (5 Ci/ml) and UV-irradiated for 30 seconds, before or after the indicated times of adding the stimulus (anti-CD3, UCHT1, or anti-TCR, Jovi1). After cell lysis, IPs were performed as indicated. Samples were separated by running two SDS-PAGE gels in parallel. One gel was dried and exposed to an X-ray film (autoradiography), and the corresponding second gel subjected to WB. Alternatively, membrane patches were prepared as outlined above, the
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TCRA state-stabilizing antibody was given at 37°C and after UV irradiation, the membranes were lysed and analysed as above.
Synthesis of beads coupled to stearate, palmitate and cholesterol
The synthesis of the stearate-, palmitate-and cholesterol-coupled sepharose beads was as described (Beck-Garcia et al., 2013) . In brief, the carboxygroups of stearate, palmitate or cholesteryl hemisuccinate were activated by N,Ndiisopropyl-ethylamine and O-(benzotriazol-1-yl)-tetramethyluronium tetrafluoroborate and coupled to -aminohexyl agarose beads. The completeness of the reaction was tested by a Kaisertest.
SH3-PD assay, lipid-PD assay, IP and immunoblotting
Lysates were subjected to the SH3-PD assay using SH3.1(Nck)-GST bound glutathionecoupled beads as described (Gil et al., 2002) . The cholesterol-, stearate-and palmitate-PD assays were also done as described (Beck-Garcia et al., 2013) ; after the PD the beads were was added to the other parts. Antibodies were allowed to bind to the scTCR on ice for 30-90 min. 7 mM cholesterol in EtOH or EtOH alone was then added when indicated. Afterwards, the scTCRs (and bound antibodies) were purified with nitro-phenol-coupled-sepharose beads.
After washing, 50 ng active, recombinant GST-Lck and 1 M ATP were added in kinasebuffer (40 mM HEPES, 10 mM MgCl2, 2 mM MnCl2) and incubated for the indicated times at 37°C. Presence of the TCRA state or antibody binding to the TCR was controlled by SH3-PD or binding to protein G-sepharose, respectively.
Upregulation of CD69
To quantify the degree of T-cell activation, we stimulated the cells for 6-7 hours with the indicated stimuli. After harvesting, cells were stained with an APC-coupled anti-CD69
antibody (Invitrogen), washed and analyzed with a Calibur (BD Biosciences) or a Gallios (Beckman Coulter) flow cytometer. Fluorescence intensities were analyzed with FlowJo 8.2
software.
Statistical analysis
Error bars depict standard error of the mean (SEM). Statistical significance and linear regression were determined with GraphPad Prism as indicated: * p < 0.05, ** p < 0.01, *** p < 0.001. The significances were calculated by Student´s t-test as indicated (see below). (B) wt scTCR-and TMchim scTCR-expressing cells were left untreated or stimulated with anti-CD3 (OKT3) for 5 min and the cholesterol-PD assay was performed as in Figure 1E (n=4).
Supplemental Information
(C) Cells treated as in (B) were subjected to the SH3-PD assay as Figure 1E (n=3).
(D) Cells treated as in (B) were lysed, an IP using OKT3 and WB were done as indicated. The ratios of the band intensities of phospho-/ (n=4-9) and phospho-/ (n=4-11) obtained from the TMchim TCR were normalized to the corresponding ratio obtained from the wt TCR, ***p<0.001 by two-sided one-sample t-test.
(E) Cells were treated as in (B) and analyzed for phospho-Erk and Erk by WB (n=5). cholesterol that cannot be cross-linked to the TCR (depicted without the star). After cell lysis, only phosphorylated TCRs were purified using an anti-phospho-tyrosine beads. Proteins were separated by reducing SDS-PAGE and an autoradiography and WB was done (n=2).
(C) Jurkat cells were left untreated or stimulated with pervanadate. The lysate was split into 3 parts; the cholesterol-and SH3-PD assays were performed (top and middle panels), and the lysates were analysed (lower panels) (n=3).
(D) TCRs are in equilibrium between the inactive (TCRI, blue), active (TCRA, red) and phosphorylated states. In resting cells, the TCRI state and phosphatase activity dominate, so that most TCRs are non-phosphorylated. The K76T TCR cannot switch to TCRA.
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(E) Jurkat cells expressing wt or K76T murine CD3 were stimulated with pervanadate. Cell numbers were adjusted to the same amount of murine CD3 molecule numbers on the cell surface. After lysis, TCRs were isolated with anti-mouse CD3 antibodies. WB was done as indicated (n=3). The SH3-PD assay was performed in parallel.
(C) Quantification of the amounts of phospho-CD3 (n=5) and phospho-Y1 (n=7) relative to CD3 and normalized to unstimulated condition is shown, ** p < 0.01, *** p < 0.001 by two-sided one-sample t-test.
(D) Membrane patches of scTCR cells were treated with anti-CD3 antibodies or left untreated. Samples were treated as in B (n=2).
(E) Cholesterol was added to purified scTCRs (chol) or not (-). Then, anti-CD3 antibodies were given and the SH3-PD was performed (n=3). In parallel, protein G-coupled sepharose was added and purified TCRs analyzed by WB.
(F) A reconstituted CD3 phosphorylation reaction was done as in (B), in the presence or absence of cholesterol (n=3). (A) Jurkat cells were grown with radioactive photocholesterol, and were either exposed to UV light and then treated with anti-CD3ε (UCHT1) or anti-TCRβ (Jovi1) antibodies for 20 min at 37°C (-); or stimulated first and then exposed to UV light (α-CD3ε, α-TCRβ). After cell lysis, additional anti-CD3ε or anti-TCRβ antibodies were added, to immunoprecipitate all TCRs using protein G-sepharose beads (lanes, 1, 2, 5, 6). Alternatively, protein G-sepharose beads alone were added, in order to capture the antibody-bound cell surface TCRs (lanes 3, 4). Purified proteins were separated and analysed as is Figure 1B. (B) Jurkat cells were grown with radioactive photocholesterol and membranes patches were prepared as described in Supplemental Experimental Procedure. Stimulation and analysis were done as in A.
(C) The SH3-PD is graphically depicted. In the TCR I state (blue), the CD3ε proline rich sequence is not available for binding to the GSTcoupled Nck SH3.1 domain bound to glutathione beads. In contrast, antibody-or pMHC-stimulated TCRs are in the active conformation (TCR A , red), allowing the proline-rich sequence to bind to the SH3-bound beads.
(D) Jurkat cells grown without photocholesterol were left unstimulated or treated with anti-CD3ε antibodies for 2 hours at 4°C. Subsequently, cells were UV irradiated or not. The SH3-PD assay and a protein G-coupled sepharose IP were performed. Purified proteins and the lysate were analysed. The data show that irradiation with UV light per se did not affect the conformational state of the TCR. (E) Human peripheral blood mononuclear cells (PBMCs) from a healthy donor were left unstimulated (-) or treated for 5 min at 37°C with anti-CD3ε (UCHT1). The cholesterol-and SH3-PD assays were performed as in Figure 1E .
(F) The TCR and the transferrin receptor (TfR) were purified from M.mζ-SBP and M.hTfR-SBP cells through the streptavidin-binding peptide (SBP) with streptavidin-coupled beads and then eluted with 4 mM biotin. The BCR was purified from J558Lmb1/δm B cells with nitro-phenol-coupled beads and eluted with 5 mM nitro-iodo-phenol. The eluates were subjected to a lipid-PD assay with uncoupled, stearate-or cholesterol-coupled sepharose beads and the bound proteins detected by WB. In the second row, the supernatant after the PD was analysed, showing that most, if not all, resting TCRs possess the capacity to bind to cholesterol. (G) Jurkat cells were stimulated as described in Figure 1E . After lysis, a PD assay with stearate-coupled beads was performed and analysed as in Figure 1E top panels.
(H) An experiment as in Figure S1G using palmitate-coupled beads was performed and analysed as in Figure 1F . We conclude that the palmitate-TCR interaction is not influenced by the conformational state of the TCR. (Backstrom et al., 1996; Petersen et al., 2004) . (C) The scTCR contains the scTCRβ chain that is composed of a single chain (sc) construct of the variable immunoglobulin (Ig) domains of a nitro-phenol (NP)-specific antibody (scFv) connected by a linker of 8 amino acids to the N terminus of wt TCRβ . NP binding to the scTCR does not influence the conformational state of the TCR . (D) wt scTCRβ and TMchim scTCRβ-expressing cells were stained with anti-human TCRβ (Jovi3) and PE-coupled anti-mouse IgG. Both scTCRβ chains (wt blue, TMchim orange) are expressed on the cell surface to equal levels. The parental 31-13 cells did not express any TCRβ chain (grey). (E) wt scTCRβ and TMchim scTCRβ were expressed in the TCRβ-deficient 31-13 Jurkat-derived cell line. These cells were lysed in 1% digitonin, the scTCR was affinity-purified by NP-sepharose beads and eluted using 5 mM free NIP. After separation by BN-PAGE, WB was done with an anti-CD3ζ antibody, showing that the TMchim TCR had the same size as the wt TCR. This suggested that the stoichiometry was the same in both TCRs. (F) Wt TCR and TMchim TCR-expressing cells were stained with the antibody Jovi1 that recognizes the constant Ig domain of TCRβ, but only when this domain is folded correctly (Huppa and Ploegh, 1997) , and with the anti-CD3 antibody UCHT1 which only recognizes folded CD3ε (Arnett et al., 2004) . A FITC-labelled secondary antibody recognizing Jovi1 and UCHT1 was used and the fluorescence intensity was measured by flow cytometry. Staining with the secondary antibody alone served to substract the background staining intensity. Triplicates were done and the ratio of the MFI (UCHT1) versus MFI (Jovi1) is displayed. Since this ratio was similar, we conclude that the TMchim TCR was folded properly concerning the two epitopes bound by these antibodies.
(G) Binding of the wt and TMchim TCR to cholesterol-(left) or palmitate (right) -coupled beads was quantified and calculated as in Figure  1F , showing that the capacity to bind to cholesterol, but not to palmitate, was reduced in the TMchim TCR compared to the wt TCR.
(H) Cells were stimulated as in Figure 2B with the exception that the stimulation lasted for 7 h. Then cells were stained with an APC-coupled anti-CD69 antibody and analysed by flow cytometry. The percent of CD69-positive living cells is displayed. This experiment shows that the mutant TCR defective in cholesterol binding is partially active in non-stimulated cells. (F) Cells were stimulated stained and analysed as in (E) with the exception that anti-phospho-ZAP70 was used instead of anti-phospho-Erk. The MFI of the phospho-ZAP70 signals were normalized to the unstimulated wt or K76T cells. Together, these experiments show that the mutant K76T TCR, which cannot switch to the TCR A , state has an impaired signalling capacity whether stimulated by antibodies (as published (Martinez-Martin et al., 2009) ) or pervanadate, which inhibits phosphatases but does not change the TCR I -TCR A equilibrium (Gil et al., 2002) . Figure 6A . In the third column the 95% confidence intervals are given in brackets. C) Lymph node cells as in Figure 6C were stained on ice for 30 min with increasing concentrations of PE-labeled wt OVA-H2-K b tetramers
(that can bind to CD8) and then with an anti-Vα2 antibody. Flow cytometry measurement to quantify the amount of bound tetramers was done as in Figure 6C (n=3), including gating on cells with similar TCR expression level and normalization to the TCR level. * p < 0.05, *** p < 0.001 by unpaired t-test. Figure 6C were used to fit to the "ligand-induced TCR clustering" model from panel A. The best fit of the model to the data is shown by solid lines, indicating that this model is also in line with the data. Thus, the clustering mechanism of the TCR does not affect the interpretation of the data. (D, E) Analyses of the "ligand-induced TCR clustering" model were done as in Figures 6D and 6E . The results are very similar, indicating that the role of cholesterol in controlling the conformational switch in the TCR and in regulating pMHC tetramer binding is independent of whether TCR are nanoclustered or clustered by the pMHC tetramer.
